Skip to main content

Table 2 Response to azacitidine[18],[19]

From: Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group

Transfusion independence, n, (% ITT*), [% IWG]  
PLT-TI 24/60 (40.0), 24/43 [55.8]
RBC-TI 35/97 (36.1), 35/69 [50.7]
Hematologic improvement, n, (% ITT), [% IWG]  
No HI 58 (37.4) [54.2]
HI-Any 49 (31.6) [45.8]
Best marrow response, n (% ITT) [% eval.§]  
CR 15 (9.7) [20.0]
mCR 5 (3.2) [6.7]
PR 32 (20.6) [42.7]
mSD 19 (12.3) [25.3]
Primary PD 4 (2.6) [5.3]
Overall response, n, (% ITT), [% IWG] 70 (45.2) [65.4]
CR 15 (9.7) [14.0]
mCR 5 (3.2) [4.7]
PR 32 (20.6) [29.9]
mSD with HI 4 (2.6) [3.7]
HI only 14 (9.0) [13.1]
No response 61 (39.4), 37 [34.6]
  1. IWG indicates International Working Group Criteria; TI, transfusion independence; HI, hematologic improvement; mCR, marrow CR; mSD, marrow stable disease; BMP, bone marrow puncture; PD, progressive disease;
  2. *Concerns all patients that were transfusion dependent at baseline;
  3. †Concerns number of patients that were transfusion dependent at baseline and received >2 cycles of azacitidine and were thus evaluable for response assessment according to IWG-criteria;
  4. ‡Evaluable according to IWG-criteria, i.e. patients that received >2 cycles of azacitidine (n = 107);
  5. §Concerns patients in whom bone marrow puncture was performed (n = 75); bone marrow assessment was performed as clinically necessary, and at the discretion of the respective treating physician; a total of 140 bone marrow punctures were performed in 75 patients (of patients in whom no bone marrow puncture was performed, 30 received only one and 18 received only two cycles of azacitidine; of these, 26 died within 2 months and a further 11 died within 6 months after stop of azacitidine treatment).